Who is sponsoring NCT05158621?

NCT05158621 is sponsored by Gritstone bio, Inc..

What drugs are being tested in NCT05158621?

Interventions in NCT05158621: blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA]).

What condition does NCT05158621 study?

NCT05158621 studies Metastatic Colorectal Cancer, Stage II/III Colon Cancer.

Is NCT05158621 still recruiting?

NCT05158621 is currently completed. Last updated 18 October 2022.

Last reviewed 2022-10-18 · How we verify

NCT05158621

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Screening Study Targeting Tumor-specific Antigens

Completed Last updated 18 October 2022

What this trial tests

trial testing blood collection for research (next generation sequencing [NGS]) in Metastatic Colorectal Cancer in 22 participants. Completed in 15 August 2022.

Timeline

14 December 2021

Primary endpoint
15 August 2022

15 August 2022

Quick facts

Lead sponsor	Gritstone bio, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	22
Start date	14 December 2021
Primary completion	15 August 2022
Estimated completion	15 August 2022
Sites	6 locations across United States

Drugs / interventions tested

blood collection for research (next generation sequencing [NGS])
blood collection for research (HLA typing)
blood collection for research (circulating tumor DNA [ctDNA])

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Stage II/III Colon Cancer — all drugs for Stage II/III Colon Cancer →

Sponsor

Gritstone bio, Inc. — full company profile →

Who can join

12 and older, any sex, with Metastatic Colorectal Cancer or Stage II/III Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify patients who may be eligible to participate in a separate Phase 2/3 treatment study evaluating an individualized neoantigen vaccine GRANITE for first line (1L) maintenance treatment of metastatic, microsatellite-sable colorectal cancer (MSS-CRC) sponsored by Gritstone bio. This may include the manufacturing of an individualized vaccine, which involves neoantigen prediction and generating a vaccine targeting neoantigens.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advanced nano-based strategies for mRNA tumor vaccine.
Qu Y, Xu J, Zhang T, Chen Q, et al · · 2024 · cited 28× · PMID 38239240 · DOI 10.1016/j.apsb.2023.07.025
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
Chakrabarti S, Kasi AK, Parikh AR, Mahipal A. · · 2022 · cited 20× · PMID 35804850 · DOI 10.3390/cancers14133078
The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.
Kye Y, Nagineni L, Gadad S, Ramirez F, et al · · 2022 · cited 7× · PMID 36077792 · DOI 10.3390/cancers14174255
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy.
Peng Y, Zhan L, Shi J, Wang J, et al · · 2025 · PMID 41079643 · DOI 10.1002/mco2.70321

Verify or expand the search:

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Gritstone bio, Inc. trials

Trials by the same sponsor.

NCT05456165 — Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients Wit · Phase 2 · withdrawn
NCT05435027 — Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Livi · Phase 1 · completed
NCT05148962 — Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers · Phase 1 · completed
NCT03953235 — A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens · Phase 1, PHASE2 · completed
NCT03639714 — A Study of a Personalized Neoantigen Cancer Vaccine · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05158621 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gritstone bio, Inc.
Last refreshed: 18 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05158621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing